ArticleRespiratory research & clinical practice2026
Evaluation of Xpert MTB/RIF Ultra performance on bronchoalveolar lavage fluid samples for pulmonary tuberculosis diagnosis.
Article in Respiratory research & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In cases in which tuberculosis is not diagnosed microbiologically through sputum samples, bronchoscopy has been the conventional method to increase diagnostic rates. Few studies have evaluated the performance of the Xpert MTB/RIF Ultra assay on BAL fluid samples. We therefore sought to evaluate the performance of Xpert MTB/RIF Ultra on BAL fluid samples for pulmonary tuberculosis diagnosis in a Brazilian city with a high incidence of tuberculosis. Methods: This was a cross-sectional study performed at a tertiary care university hospital in southern Brazil. Patients > 18 years of age with respiratory symptoms suggestive of pulmonary tuberculosis were invited to participate. Test results were collected, including smear microscopy, mycobacterial culture, and Xpert MTB/RIF Ultra on BAL fluid samples. Results: During the study period, 161 patients met the inclusion criteria and were therefore included in the analysis. With culture being considered the gold standard, the sensitivity, specificity, positive predictive value, and negative predictive value of Xpert MTB/RIF Ultra on BAL fluid samples were 97.3% (95% CI, 90.6-99.7), 94.3% (95% CI, 87.1-98.1), 93.5% (95% CI, 86.0-97.1), and 97.6% (95% CI, 91.3-99.4), respectively. Conclusions: The Xpert MTB/RIF Ultra assay showed high sensitivity and specificity on BAL fluid samples from individuals with presumptive pulmonary tuberculosis. This demonstrates that the test is a useful tool for pulmonary tuberculosis diagnosis under programmatic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.